AGWCA
RCUS icon

Annis Gardner Whiting Capital Advisors’s Arcus Biosciences RCUS Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48
Closed -$1.04K – 1037
2026
Q1 		$1.04K Hold
48
– – ﹤0.01% 1143
2025
Q4 		$1.14K Hold
48
– – ﹤0.01% 1030
2025
Q3 		$653 Hold
48
– – ﹤0.01% 1048
2025
Q2 		$391 Buy
+48
New +$410 ﹤0.01% 1211

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's RCUS Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 48 shares — an estimated $1.04K sold.

Annis Gardner Whiting Capital Advisors first reported a position in RCUS in Q2 2025 and held it in 4 quarters. The position peaked at $1.14K in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 48 Arcus Biosciences shares in Q2 2026, an estimated $1.04K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Arcus Biosciences in Q2 2025 and held it in 4 quarters.
  • Annis Gardner Whiting Capital Advisors's Arcus Biosciences position peaked at $1.14K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.